Bayer said investigational drug elinzanetant met its primary goal by reducing symptoms linked to menopause in a late-stage clinical trial, paving the way for submissions to health authorities for approval.

The German pharmaceutical-and-agricultural group said Tuesday that elinzanetant showed a statistically significant reduction in the frequency of moderate to severe vasomotor symptoms, also known as hot flashes, compared to placebo. The long-term safety profile observed over 52 weeks in the phase 3 trial is overall consistent with previously conducted studies, the company said.

The study comes after Bayer reported positive results for two late-stage studies of the same drug.

Bayer said it will submit data from the studies to health authorities for approval of elinzanetant for the treatment of moderate to severe vasomotor symptoms associated with menopause.